Search results
Showing 16 to 30 of 33 results for semaglutide
Awaiting development Reference number: GID-TA11847 Expected publication date: TBC
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
Oral semaglutide for managing overweight and obesity [ID6188]
Discontinued Reference number: GID-TA11149
In development Reference number: GID-TA11104 Expected publication date: TBC
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use